In a surprising development, Indian pharmaceutical stocks experienced a significant downturn on Monday, despite broader market gains. The Nifty Pharma Index dropped by 1.3%, while the Nifty 50 Index $^NSEI rose by 2.4%. This decline came after U.S. President Donald Trump announced plans to sign an executive order aimed at reducing prescription drug prices in the U.S. to levels consistent with those in other high-income countries. The new policy could reduce drug prices by 30-80%, posing a potential threat to the revenue streams of Indian pharmaceutical companies that have long relied on the U.S. market for a large portion of their sales.